Edition:
United Kingdom

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

3.95USD
20 Jun 2018
Change (% chg)

$-0.30 (-7.06%)
Prev Close
$4.25
Open
$4.25
Day's High
$4.28
Day's Low
$3.92
Volume
176,038
Avg. Vol
98,408
52-wk High
$8.60
52-wk Low
$3.78

Chart for

About

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and... (more)

Overall

Beta: 0.24
Market Cap(Mil.): $268.07
Shares Outstanding(Mil.): 47.45
Dividend: --
Yield (%): --

Financials

  ARDX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.44 -- --
ROI: -79.45 2.00 14.38
ROE: -79.86 3.49 16.08

BRIEF-Ardelyx Announces Pricing Of Public Offering Of Common Stock

* ARDELYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

22 May 2018

BRIEF-Ardelyx Announces Proposed Public Offering Of Common Stock

* ARDELYX INC - STARTED UNDERWRITTEN PUBLIC OFFERING OF UP TO $50 MLN OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

21 May 2018

BRIEF-Ardelyx Reports Qtrly Loss Per Share $0.36

* ARDELYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

08 May 2018

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

* KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​

19 Mar 2018

BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21

* ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS

14 Mar 2018

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage:

08 Jan 2018

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

03 Jan 2018

Earnings vs. Estimates